Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Therapy development for ALS: lessons learned and path forward.

Veena Lanka1, Merit Cudkowicz

  • 1Neurology Clinical Trials Unit, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, USA.

Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases
|June 25, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Author Correction: Autoimmune response to C9orf72 protein in amyotrophic lateral sclerosis.

Nature·2026
Same author

Safety and Efficacy of PrimeC in Amyotrophic Lateral Sclerosis: The PARADIGM Randomized Clinical Trial.

JAMA neurology·2026
Same author

ALS untangled #83: clenbuterol.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026
Same author

Autoimmune response to C9orf72 protein in amyotrophic lateral sclerosis.

Nature·2025
Same author

ENLITE PD: A Randomized Clinical Trial of Light Therapy for Impaired Sleep in Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2025
Same author

A Phase-2B Double-Blind Randomized International Prospective Trial of Inebilizumab in NMDAR Encephalitis: The ExTINGUISH Trial.

Neurology open access·2025
Same journal

Abstracts of the 23rd International Symposium on ALS/MND. December 5-7, 2012. Chicago, Illinois, USA.

Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases·2014
Same journal

Energy requirement assessed by doubly-labeled water method in patients with advanced amyotrophic lateral sclerosis managed by tracheotomy positive pressure ventilation.

Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases·2012
Same journal

The impact of active coping strategies on survival in ALS: the first pilot study.

Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases·2012
Same journal

Unusual occurrence of amyotrophic lateral sclerosis in myasthenia gravis.

Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases·2012
Same journal

Economic cost of home-telemonitoring care for BiPAP-assisted ALS individuals.

Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases·2012
Same journal

Replication of association of CHRNA4 rare variants with sporadic amyotrophic lateral sclerosis: the Italian multicentre study.

Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases·2012
See all related articles

Translating promising motor neuron disease therapies from preclinical success to human trials requires addressing past failures. Improving clinical trial design and developing better biomarkers are crucial for advancing treatments for amyotrophic lateral sclerosis (ALS).

Area of Science:

  • Neuroscience
  • Clinical Trials
  • Drug Development

Background:

  • Preclinical models show promise for motor neuron disease therapies.
  • Many promising treatments have failed in human clinical studies.
  • Past failures may stem from incorrect therapeutic targets or flawed trial design.

Purpose of the Study:

  • To review treatment development in amyotrophic lateral sclerosis (ALS).
  • To discuss the strengths and limitations of past ALS clinical trials.
  • To identify critical needs for future ALS therapy development.

Main Methods:

  • Review of existing literature on ALS treatment development.
  • Analysis of past clinical trial designs and outcomes.
  • Identification of challenges and unmet needs in ALS research.

Related Experiment Videos

Main Results:

  • Several promising therapies failed in human trials, necessitating a re-evaluation of strategies.
  • Past clinical trials for ALS have exhibited significant limitations.
  • A critical need exists for improved biomarkers and markers of biological activity.

Conclusions:

  • Future ALS therapy development must address reasons for past trial failures.
  • Enhanced clinical trial design, including robust Phase I and II studies, is essential.
  • Development of better biomarkers and activity markers is critical for successful Phase III trials.